Precision medicine: the foundation of future cancer therapeutics

Código QR

Precision medicine: the foundation of future cancer therapeutics

Guardado en:

Detalles Bibliográficos
Autores principales:	Seung Ho Shin, Ann M. Bode, Zigang Dong
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/bfa4019ac8c64cc186c83fa25d3a406a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Precision oncology- the future of personalized cancer medicine?
por: Ann M. Bode, et al.
Publicado: (2017)

Live-single-cell phenotypic cancer biomarkers-future role in precision oncology?
por: Grannum R. Sant, et al.
Publicado: (2017)

Targeting ornithine decarboxylase (ODC) inhibits esophageal squamous cell carcinoma progression
por: Wei He, et al.
Publicado: (2017)

Development and pilot of an online, personalized risk assessment tool for a breast cancer precision medicine trial
por: Holly Keane, et al.
Publicado: (2021)

Targeting the epichaperome as an effective precision medicine approach in a novel PML-SYK fusion acute myeloid leukemia
por: Mayumi Sugita, et al.
Publicado: (2021)

Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study
por: Apostolia Maria Tsimberidou, et al.
Publicado: (2021)

PD-L1 quantification across tumor types using the reverse phase protein microarray: implications for precision medicine
por: Mariaelena Pierobon, et al.
Publicado: (2021)

Precision cell-free DNA extraction for liquid biopsy by integrated microfluidics
por: Hoyoon Lee, et al.
Publicado: (2020)

Artificial intelligence for the next generation of precision oncology
por: Pedro J. Ballester, et al.
Publicado: (2021)

Inhibiting breast cancer by targeting the thromboxane A2 pathway
por: Haitao Li, et al.
Publicado: (2017)

Precision cancer therapy is impacted by oncogene-dependent epigenome remodeling
por: Feng Liu, et al.
Publicado: (2017)

Circulating tumor cells: quintessential precision oncology presenting challenges for biology
por: Rebecca J. Morris
Publicado: (2017)

Network-based machine learning and graph theory algorithms for precision oncology
por: Wei Zhang, et al.
Publicado: (2017)

Structural variant detection in cancer genomes: computational challenges and perspectives for precision oncology
por: Ianthe A. E. M. van Belzen, et al.
Publicado: (2021)

Precision histology: how deep learning is poised to revitalize histomorphology for personalized cancer care
por: Ugljesa Djuric, et al.
Publicado: (2017)

Correction: Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies
Publicado: (2021)

Criteria-based curation of a therapy-focused compendium to support treatment recommendations in precision oncology
por: Frank P. Lin, et al.
Publicado: (2021)

Breast reconstruction: current and future options
por: Paul Jr H, et al.
Publicado: (2011)

A computational method for prioritizing targeted therapies in precision oncology: performance analysis in the SHIVA01 trial
por: Istvan Petak, et al.
Publicado: (2021)

Swiss-PO: a new tool to analyze the impact of mutations on protein three-dimensional structures for precision oncology
por: Fanny S. Krebs, et al.
Publicado: (2021)

Implications for breast cancer dormancy in other areas of medicine
por: Rameshwar P
Publicado: (2012)

AXL receptor tyrosine kinase as a therapeutic target in NSCLC
por: Okimoto RA, et al.
Publicado: (2015)

Biliary Tract Cancers: Treatment Updates and Future Directions in the Era of Precision Medicine and Immuno-Oncology
por: Ashish Manne, et al.
Publicado: (2021)

Challenges in the development of future treatments for breast cancer stem cells
por: Shyam A Patel, et al.
Publicado: (2010)

Digital Display Precision Predictor: the prototype of a global biomarker model to guide treatments with targeted therapy and predict progression-free survival
por: Vladimir Lazar, et al.
Publicado: (2021)

Epiregulin as a therapeutic target in non-small-cell lung cancer
por: Sunaga N, et al.
Publicado: (2015)

PI3K mutations in breast cancer: prognostic and therapeutic implications
por: Mukohara T
Publicado: (2015)

MET targeted therapy for lung cancer: clinical development and future directions
por: Feng Y, et al.
Publicado: (2012)

Traditional Chinese Medicine Therapy for Esophageal Cancer: A Literature Review
por: Luchang Cao MB, et al.
Publicado: (2021)

Targeting immunogenic cancer cell death by photodynamic therapy: past, present and future
por: Razan Alzeibak, et al.
Publicado: (2021)

Emerging role of G9a in cancer stemness and promises as a therapeutic target
por: Joshua R. Haebe, et al.
Publicado: (2021)

Single nucleotide polymorphisms as susceptibility, prognostic, and therapeutic markers of nonsmall cell lung cancer
por: Zienolddiny S, et al.
Publicado: (2011)

Therapeutic reduction mammoplasty in large-breasted women with cancer using superior and superomedial pedicles
por: Denewer A, et al.
Publicado: (2012)

Safety and esthetic outcomes of therapeutic mammoplasty using medial pedicle for early breast cancer
por: Roshdy S, et al.
Publicado: (2015)

Correction: Targeting immunogenic cancer cell death by photodynamic therapy: past, present and future
Publicado: (2021)

Molecular stratification of early breast cancer identifies drug targets to drive stratified medicine
por: Jane Bayani, et al.
Publicado: (2017)

Surrogate endpoints for early-stage breast cancer: a review of the state of the art, controversies, and future prospects
por: María Gion, et al.
Publicado: (2021)

Hapten-enhanced therapeutic effect in advanced stages of lung cancer by ultra-minimum incision personalized intratumoral chemoimmunotherapy therapy
por: Yu BF, et al.
Publicado: (2015)

Oral Chinese Patent Medicine Combined With Oxaliplatin-Based Chemotherapy Regimen for the Treatment of Colorectal Cancer: A Network Meta-Analysis
por: Mo Tang PhD Student, et al.
Publicado: (2021)

Multiscale-omic assessment of EWSR1-NFATc2 fusion positive sarcomas identifies the mTOR pathway as a potential therapeutic target
por: Nathan D. Seligson, et al.
Publicado: (2021)